AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

11,220.00p
   
  • Change Today:
    -196.00p
  • 52 Week High: 13,276.00p
  • 52 Week Low: 9,725.00p
  • Currency: UK Pounds
  • Shares Issued: 1,550.61m
  • Volume: 131,430
  • Market Cap: £173,978m
  • RiskGrade: 123

AstraZeneca Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.
Registrars: Equiniti
Brands: Losec, Prilosec, Nexium, Crestor

Key Personnel

Senior Independent Non-Executive Director: Philip A J Broadley
CEO and Executive director: Pascal Soriot
CFO & Executive Director: Aradhana Sarin
Chairman: Michel Demare
Independent Non-Executive Director: Euan Ashley
Independent Non-Executive Director: Deborah DiSanzo
Independent Non-Executive Director: Diana Layfield
Independent Non-Executive Director: Tony Mok
Independent Non-Executive Director: Nazneen Rahman
Independent Non-Executive Director: Sheri McCoy
Non-Executive Dir: Anna Manz, Marcus Wallenberg, Rene Haas, Birgit Conix , Andreas Rummelt

Contact Details

Address: 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge,United Kingdom, CB2 0AA
Phone: +44 (0)20 3749 5000
Fax: +44 (0)20 7604 8151
Website: http://www.astrazeneca.com

Listings

Sector: Pharma and Biotech(LSE)
Index: FTSE 100, FTSE 350, FTSE All-Share
Overseas Listings: BATSLON:AZNL
ISIN: GB0009895292

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 11,220.00p
Change Today -196.00p
% Change -1.72 %
52 Week High 13,276.00p
52 Week Low 9,725.00p
Volume 131,430
Shares Issued 1,550.61m
Market Cap £173,978m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
93.34% below the market average93.34% below the market average93.34% below the market average93.34% below the market average93.34% below the market average
87.23% below the sector average87.23% below the sector average87.23% below the sector average87.23% below the sector average87.23% below the sector average
Price Trend
41.51% above the market average41.51% above the market average41.51% above the market average41.51% above the market average41.51% above the market average
51.02% above the sector average51.02% above the sector average51.02% above the sector average51.02% above the sector average51.02% above the sector average
Income
65.81% below the market average65.81% below the market average65.81% below the market average65.81% below the market average65.81% below the market average
14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average
Growth
85.34% above the market average85.34% above the market average85.34% above the market average85.34% above the market average85.34% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average

What The Brokers Say

Strong Buy 10
Buy 15
Neutral 4
Sell 0
Strong Sell 0
Total 29
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 20-Feb-25 08-Aug-24
Paid 24-Mar-25 09-Sep-24
Amount 210.00¢ 100.00¢

Trades for 31-Mar-2025

Time Volume / Share Price
11:35 26 @ 11,220.00p
11:35 13 @ 11,220.00p
11:35 36 @ 11,220.00p
11:35 38 @ 11,220.00p
11:35 35 @ 11,220.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page